Dodecanoic acid, 3-[[2-(2-hydroxyethoxy)ethyl]imino]-2,2-dimethylpropyl ester

Acute Toxicity: oral

Administrative data

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2008-11-05 to 2009-04-09

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2009

Report date:

2009

Materials and methods

Test guideline

Test guideline 1

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

no

Test guideline 2

Qualifier:

according to guideline

Guideline:

EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)

Version / remarks:

2008

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

3-{[2-(2-hydroxyethoxy)ethyl]imino}-2,2-dimethylpropyl dodecanoate

EC Number:

700-067-2

Cas Number:

931419-77-1

Molecular formula:

C21H41NO4

IUPAC Name:

3-{[2-(2-hydroxyethoxy)ethyl]imino}-2,2-dimethylpropyl dodecanoate

Test material form:

liquid

Test animals

Species:

rat

Strain:

Wistar

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River (Europe) Laboratories Inc.
TOXI COOP Ltd. 1103 Budapest, Cserkesz u. 90.
- Age at study initiation: Young adult rats, 7 weeks old
- Weight at study initiation: 172 – 183 g
- Housing: Group caging (3 animals/cage)
- Diet: ssniff SM R/M-Z+H, ad libitum
- Water: tap water from municipal supply, ad libitum
- Acclimation period: 6 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.3 - 23.8 °C
- Humidity (%): 34 - 59 %
- Air changes (per hr): 8-12 air exchanges/hour by central air-condition system.
- Photoperiod (hrs dark / hrs light): 12 hours daily, from 6.00 a.m. to 6.00 p.m.

Administration / exposure

Route of administration:

oral: gavage

Vehicle:

unchanged (no vehicle)

Doses:

2000 mg/kg bw

No. of animals per sex per dose:

6 female animals (nulliparous, non pregnant)
3 animals/step

Control animals:

no

Details on study design:

Animals were observed daily for 14 days after dosing.

Results and discussion

Preliminary study:

No preliminary study was conducted.

Effect levels

Effect levels 1

Sex:

female

Dose descriptor:

LD0

Effect level:

> 2 000 mg/kg bw

Effect levels 2

Key result

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Mortality:

Sika Hardener LG did not cause mortality at 2000 mg/kg bw.

Clinical signs:

other: Treatment group 1 – 2000 mg/kg bw Treating with Sika Hardener LG at a dose level of 2000 mg/kg bw did not cause any adverse treatment related effects in this dose group. Treatment group 2 – 2000 mg/kg bw Treating with Sika Hardener LG at a dose level of

Gross pathology:

2000 mg/kg bw – Treatment group 1
Irregular surface of the liver, mottled pale areas and focal dark red discolouration of the lung and uterus in oestrus was observed in this dose group.

2000 mg/kg bw – Treatment group 2
Dark red focuses on the lung was recorded in this dose group.

In summary, a single oral gavage treatment with Sika Hardener LG did not cause any test article related adverse effects, all findings were typical of rats following euthanasia and exsanguination

Other findings:

No other findings.

Applicant's summary and conclusion

Interpretation of results:

GHS criteria not met

Conclusions:

Under the conditions of the present study, a single oral administration of the test item Sika Hardener LG at a dose level of 2000 mg/kg bw did not cause any treatment related adverse effects.

Executive summary:

Two groups of three female Wistar rats were treated with Sika Hardener LG by a single oral (gavage) administration at a dose level of 2000 mg/kg bw according to EU B.1 method and OECD guideline no. 423. No mortalities were recorded. No clinical signs were observed during the 14 days observation period. The body weight gain of the animals was considered normal, with no indication of test item related effects. The macroscopic examination revealed some minor alterations, such as Irregular surface of the liver, mottled pale areas and focal dark red discolouration of the lung and uterus. However, these changes were considered incidental and it was concluded that under the conditions of the present study, a single oral administration of the test item Sika Hardener LG, at a dose level of 2000 mg/kg bw (limit dose) did not cause any treatment related adverse effects. Therefore, the acute oral LD0 and LD50 values of Sika Hardener LG were determined to be greater than 2000 mg/kg bw. Based on the results of the study and according to the criteria of the relevant test guidelines no further testing was performed.